INDICATIONS FOR LT
Patients were listed for LT when King's College criteria and Clichy's criteria for LT were met in 2 consecutive blood tests and when there were no contraindications for the transplant. King's College and Clichy's criteria were calculated based on the results of blood tests obtained on admission and were recalculated every 12 hours until p-ALF was resolved, LT was performed, or death ensued.
MARS PROCEDURE
MARS treatment was used in our institution in patients diagnosed with p-ALF, who were on the waiting list for LT, and who presented HE 2, HRF, or when the cause of the p-ALF was poisoning from a drug that could potentially be cleansed by MARS.
A double-lumen dialysis catheter adjusted to the patient's weight was previously placed preferably in 1 of the internal jugular veins.
Heparin was infused in the system to achieve the appropriate anticoagulation for the maintenance of the extracorporeal circuit. Initially, heparin sodium was started using a continuous infusion at 5 IU/kg/hour. The infusion rate can be increased to 10 U/kg/hour in case of a drop of the filter pressure above 30% of the basal after the exclusion of other reasonable causes.
Abbreviations: ALT, alanine aminotransferase; ELS, extracorporeal liver support system; HE, hepatic encephalopathy; HRF, hepatorenal failure; ICG-PDR, indocyanine green plasma disappearance rate; INR, international normalized ratio; LT, liver transplantation; MARS, Molecular Adsorbent Recirculating System; p-ALF, pediatric acute liver failure; PICU, Pediatric Intensive Care Unit.
Although standard therapy was extended to 8 hours, continuous MARS treatment was planned to be performed with a kit change every 24 hours. If it was not possible to reach 24 hours of treatment, daily sessions of at least 6-8 hours were considered. These long sessions were applied in order to avoid the hemodynamic instability that can be observed at the start of each new session in very small patients. During these 24 hours, a bile acids determination was performed before and after anion exchange resins filter use in order to assess system saturation. If a prefilter and postfilter bile acids gap below 5 mmol/L was detected, then the filter was changed under sterile conditions.
The blood flow rate of the MARS filter will depend on the patient's weight (<15 kg, 80-100 mL/minute; 15-30 kg, 100-180 mL/minute; and >30 kg, 200-400 mL/minute), and it will be given by the PRISMA pump. The albumin flow rate will be the same as the prescribed blood flow in the PRISMA pump but with a maximum flow rate of 200 mL/minute.
STATISTICAL ANALYSIS
Continuous variables are presented as median (range), and categorical variables are presented as n (%). Differences in biochemical parameters before and after treatment were assessed with the paired Student t test for normally distributed values and with the Wilcoxon signed rank test for nonnormally distributed values. The statistical package for the social sciences, version 18.0 (SPSS Inc., Chicago, IL) was used for the analysis. The significance level was set at 0.05.
Results
From January 2002 to December 2016, 11 p-ALF patients fulfilled criteria for MARS treatment (7 suffering HE 2, 1 HRF, and 3 both of them). Patients' characteristics are shown in Table 1 .
EFFICACY AND SAFETY
A total of 27 MARS runs were performed in 11 patients (2.5 runs/patient). A total of 18 runs were successfully extended beyond 8 hours (median time, 19 hours; range, 16-24 hours). In the remaining 9 runs due to system problems, the sessions were done during a median time of 6.9 hours (6.2-8.0 hours). Problems detected were as follows: decreased flow in the outflow catheter branch (3 patients), high pressure in the MARS filter due to clotting problems (5 runs), and bobbles in the MARS circuit. Two patients, weighing < 10 kg, presented with hemodynamic instability at the MARS start with the need of vasoactive drugs increase. However, these were transient alterations during the first few moments of the treatment. After that, no other problems in terms of infections, bleeding, or other alterations related to MARS use were observed.
MARS dialysis was effective in removing the albumin-bound and water-soluble products and improving the inotropic score of patients. Data regarding pre-and post-MARS treatment differences are shown in Table 2 .
Out of 27 runs, 16 needed changes in the anion exchange resins filter. All filter changes were performed in longer than 8-hour runs. No complications related to long treatments or filter changes were observed.
Out of 11 patients, 10 (90.9%) presented with irreversible liver failure, and 8 of them (72.7%) had been transplanted. All MARS-treated transplanted patients were alive at the end of the study with a median follow-up of 7.6 years (5.5-14.4 years).
Discussion
Despite MARS being the most commonly used ELS device in the pediatric population, scarce data are available in the literature. Lexmond et al. (4) have documented the capacity of MARS to depurate both albumin-bound and water-soluble toxins, improving the HE in 30% of pediatric patients.
Our study also suggests that in p-ALF patients, MARS can significantly reduce the plasma concentration of protein-bound and water-soluble toxins.
MARS was well tolerated without presenting higher rates of bleeding, infections, or other complications related to its use. Although in very young infants the start of the treatment can produce hemodynamic instability, that situation is temporary and can be minimized by using prolonged treatments. Moreover, this instability is mainly observed in the first run, when the patient is more unstable. In fact, after MARS treatment, the use of vasoactive drugs was statistically significantly lower than pretreatment represented by a lower inotropic index. This stabilizing effect can be explained by the depuration of vasodilator toxins, which play a main role in the physiopathological process of some acute liver failure-related complications such as hemodynamic instability or HRF.
Although 6-8 hours is the conventional treatment duration, the MARS circuit was intended to be used for up to 24 hours according to the manufacturer. Some authors have suggested that improvements observed in HE and HRF can be greater in a longerthan-conventional treatment duration. (2) Considering that and the instability observed in the treatment start in small patients, we decided to prolong the MARS runs to 24 hours, if possible. Longer than 24-hourlong treatments were linked to MARS circuit breaks, and an albumin leakage with the air inlet in the circuit would appear. In that case, the system would stop without any other complication than a filter change. In long treatments, especially in very cholestatic patients, the exchange resin filter was changed if no biliary acid gap was detected before and after filtering. No complications were observed during these procedures.
In conclusion, long MARS treatments were safely used in p-ALF patients listed for LT in our hospital. Randomized controlled trials in children with p-ALF comparing MARS dialysis and conventional medical treatment are needed to assess the potential impact of MARS on survival.
